Wedbush Predicts Reduced Earnings for Werewolf Therapeutics

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) – Equities research analysts at Wedbush lowered their FY2025 earnings per share estimates for Werewolf Therapeutics in a research note issued to investors on Wednesday, March 12th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($1.84) per share for the year, down from their previous estimate of ($0.97). Wedbush currently has a “Outperform” rating and a $8.00 target price on the stock. The consensus estimate for Werewolf Therapeutics’ current full-year earnings is ($1.56) per share. Wedbush also issued estimates for Werewolf Therapeutics’ FY2026 earnings at ($1.13) EPS, FY2027 earnings at ($1.57) EPS, FY2028 earnings at ($1.63) EPS and FY2029 earnings at ($0.63) EPS.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Tuesday, March 11th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.03). Werewolf Therapeutics had a negative return on equity of 58.83% and a negative net margin of 578.80%.

A number of other research firms have also recently commented on HOWL. JMP Securities reduced their price objective on Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating for the company in a research report on Tuesday, January 14th. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Werewolf Therapeutics in a research report on Wednesday, March 12th.

Werewolf Therapeutics Trading Down 0.9 %

Shares of NASDAQ:HOWL opened at $1.16 on Monday. The company has a market cap of $52.00 million, a P/E ratio of -0.76 and a beta of 0.37. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10. Werewolf Therapeutics has a 1 year low of $1.03 and a 1 year high of $6.89. The stock’s fifty day moving average price is $1.34 and its 200-day moving average price is $1.79.

Institutional Trading of Werewolf Therapeutics

Hedge funds have recently bought and sold shares of the company. Walleye Capital LLC increased its position in Werewolf Therapeutics by 10.7% in the third quarter. Walleye Capital LLC now owns 108,968 shares of the company’s stock worth $231,000 after buying an additional 10,528 shares in the last quarter. PFM Health Sciences LP increased its position in Werewolf Therapeutics by 4.9% in the third quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock worth $7,205,000 after buying an additional 157,673 shares in the last quarter. State Street Corp increased its position in Werewolf Therapeutics by 12.4% in the third quarter. State Street Corp now owns 476,439 shares of the company’s stock worth $1,010,000 after buying an additional 52,528 shares in the last quarter. XTX Topco Ltd purchased a new stake in Werewolf Therapeutics in the third quarter worth about $45,000. Finally, Barclays PLC increased its position in Werewolf Therapeutics by 130.1% in the third quarter. Barclays PLC now owns 54,810 shares of the company’s stock worth $116,000 after buying an additional 30,990 shares in the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.